Drugs / Tdap
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00263679 | Nov 2003 → May 2004 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-29 | GlaxoSmithKline | Results GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation gsk.com ↗
Real-world data shows an association between Recombinant Zoster Vaccine (RZV) and potential reduced risk of dementia, consistent with growing evidence1,2,3,4 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-29 | GlaxoSmithKline | GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | “GSK Biologicals' Tdap 0.3 mg Candidate Vaccine” NCT00263679 ↗ |
| Modality | Vaccine | “candidate Tdap vaccine” NCT00263679 ↗ |